Competitors turn eyes to domestic anti-migraine market

Published: 2004-10-13 07:00:00

Updated: 2004-10-13 07:00:00

Riding on a tidal wave of better public awareness on migraine, a number of new players are poised to enter the domestic market for gaining a bigger share, albeit its smaller annual market size valued at 7.0 billion won even including OTC products.

New strong competitors among pharmaceutical firms in their moves to advance into the domestic anti-migraine drug market will be SK Pharm (UK-based...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.